First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
This study validated the P-score for the first time in a non-European population, confirming its predictive power in an Asian high-risk setting. The reclassification of 19.6% of patients suggests that the P-score refines risk stratification beyond NCCN, offering a more precise distinction between favourable and unfavourable outcomes, enabling more informed treatment decisions. These findings highlight the global applicability of the P-score and its potential to improve risk assessment and personalized treatment for PCa patients worldwide.
Authors
- See‐Tong Pang (ORCID: https://orcid.org/0000-0002-2064-0828)
- I‐Hung Shao (ORCID: https://orcid.org/0000-0002-4832-0113)
- Chen-I Hsieh (ORCID: https://orcid.org/0000-0003-3715-0363)
- Li‐Di Xu (ORCID: https://orcid.org/0000-0002-3780-4972)
- Cheng‐Keng Chuang (ORCID: https://orcid.org/0000-0001-6154-1220)
- Kai‐Jie Yu (ORCID: https://orcid.org/0000-0003-3656-8856)
- Emelie Berglund (ORCID: https://orcid.org/0000-0003-1857-307X)
- Wen‐Hui Weng (ORCID: https://orcid.org/0000-0002-6021-0451)
- Po‐Hung Lin (ORCID: https://orcid.org/0000-0002-7731-1443)
- Ting‐Yu Chang (ORCID: https://orcid.org/0000-0002-0561-2757)
- Yu Chen (ORCID: https://orcid.org/0000-0002-7600-2307)
Institutions
- National Taipei University of Technology (TW)
- Chang Gung University (TW)
- National Tsing Hua University (TW)
- Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/bco2.70026
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Chang Gung Medical Foundation